| Literature DB >> 26068201 |
Karim Labreche1, Iva Simeonova2, Aurélie Kamoun3, Vincent Gleize2, Daniel Chubb4, Eric Letouzé3, Yasser Riazalhosseini5, Sara E Dobbins4, Nabila Elarouci3, Francois Ducray6, Aurélien de Reyniès3, Diana Zelenika7, Christopher P Wardell8, Mathew Frampton4, Olivier Saulnier2, Tomi Pastinen5, Sabrina Hallout9, Dominique Figarella-Branger10, Caroline Dehais11, Ahmed Idbaih12, Karima Mokhtari13, Jean-Yves Delattre12, Emmanuelle Huillard2, G Mark Lathrop5, Marc Sanson12, Richard S Houlston4.
Abstract
Anaplastic oligodendroglioma (AO) are rare primary brain tumours that are generally incurable, with heterogeneous prognosis and few treatment targets identified. Most oligodendrogliomas have chromosomes 1p/19q co-deletion and an IDH mutation. Here we analysed 51 AO by whole-exome sequencing, identifying previously reported frequent somatic mutations in CIC and FUBP1. We also identified recurrent mutations in TCF12 and in an additional series of 83 AO. Overall, 7.5% of AO are mutated for TCF12, which encodes an oligodendrocyte-related transcription factor. Eighty percent of TCF12 mutations identified were in either the bHLH domain, which is important for TCF12 function as a transcription factor, or were frameshift mutations leading to TCF12 truncated for this domain. We show that these mutations compromise TCF12 transcriptional activity and are associated with a more aggressive tumour type. Our analysis provides further insights into the unique and shared pathways driving AO.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26068201 PMCID: PMC4490400 DOI: 10.1038/ncomms8207
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 17.694